Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTLD-2: Risk-stratified sequential rituximab SC-based therapy for post-transplant lymphoproliferative disorder
2013-004479-11Phase 2Completed
- Sponsor
- DIAKO
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in Post-Transplant Lymphoproliferative Disorder (PTLD) (3 arms), sponsored by DIAKO. Started May 2014; status: completed.
02
Drugs
rituximab
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on 2013-004479-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004479-11.